| Side-effect management of chimeric antigen receptor (CAR) T-cell therapy ML Schubert, M Schmitt, L Wang, CA Ramos, K Jordan, C Müller-Tidow, ... Annals of oncology 32 (1), 34-48, 2021 | 319 | 2021 |
| Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML) S Hofmann, ML Schubert, L Wang, B He, B Neuber, P Dreger, ... Journal of clinical medicine 8 (2), 200, 2019 | 116 | 2019 |
| Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients JM Hoffmann, ML Schubert, L Wang, A Hückelhoven, L Sellner, S Stock, ... Frontiers in immunology 8, 1956, 2018 | 100 | 2018 |
| Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients S Stock, R Übelhart, ML Schubert, F Fan, B He, JM Hoffmann, L Wang, ... International journal of cancer 145 (5), 1312-1324, 2019 | 72 | 2019 |
| A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy CK Stein-Thoeringer, NY Saini, E Zamir, V Blumenberg, ML Schubert, ... Nature medicine 29 (4), 906-916, 2023 | 68 | 2023 |
| Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations K Rejeski, M Subklewe, M Aljurf, E Bachy, A Balduzzi, P Barba, B Bruno, ... Blood 142 (10), 865-877, 2023 | 62 | 2023 |
| Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL F Korell, S Laier, S Sauer, K Veelken, H Hennemann, ML Schubert, ... Cells 9 (5), 1225, 2020 | 62 | 2020 |
| Chimeric antigen receptor transduced T cells: Tuning up for the next generation ML Schubert, JM Hoffmann, P Dreger, C Müller‐Tidow, M Schmitt International journal of cancer 142 (9), 1738-1747, 2018 | 61 | 2018 |
| Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients F Fan, HJ Yoo, S Stock, L Wang, Y Liu, ML Schubert, S Wang, B Neuber, ... International journal of cancer 148 (2), 419-428, 2021 | 53 | 2021 |
| Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia and lymphoma in the context of stem cell transplantation ML Schubert, A Hückelhoven, JM Hoffmann, A Schmitt, P Wuchter, ... Human Gene Therapy 27 (10), 758-771, 2016 | 45 | 2016 |
| Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients ML Schubert, A Schmitt, B Neuber, A Hückelhoven-Krauss, A Kunz, ... Blood 134, 51, 2019 | 44 | 2019 |
| Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells W Gong, JM Hoffmann, S Stock, L Wang, Y Liu, ML Schubert, B Neuber, ... Cancer Immunology, Immunotherapy 68, 1195-1209, 2019 | 39 | 2019 |
| Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG. CD19. CD28. 4-1BBzeta retroviral vector: a unicentre phase I … ML Schubert, A Schmitt, L Sellner, B Neuber, J Kunz, P Wuchter, A Kunz, ... Bmj Open 9 (5), e026644, 2019 | 38 | 2019 |
| Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data P Derigs, A Radujkovic, ML Schubert, P Schnitzler, T Schöning, ... Annals of Hematology 100, 2087-2093, 2021 | 37 | 2021 |
| Optimized assessment of qPCR-based vector copy numbers as a safety parameter for GMP-grade CAR T cells and monitoring of frequency in patients A Kunz, U Gern, A Schmitt, B Neuber, L Wang, A Hückelhoven-Krauss, ... Molecular Therapy-Methods & Clinical Development 17, 448-454, 2020 | 35 | 2020 |
| CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison P Dreger, S Dietrich, ML Schubert, L Selberg, A Bondong, M Wegner, ... Blood advances 4 (24), 6157-6168, 2020 | 34 | 2020 |
| Pre-sensitization of malignant B cells through venetoclax significantly improves the cytotoxic efficacy of CD19. CAR-T cells M Yang, L Wang, M Ni, B Neuber, S Wang, W Gong, T Sauer, L Sellner, ... Frontiers in Immunology 11, 608167, 2020 | 29 | 2020 |
| The potential role of the intestinal micromilieu and individual microbes in the immunobiology of chimeric antigen receptor T-cell therapy ML Schubert, R Rohrbach, M Schmitt, CK Stein-Thoeringer Frontiers in immunology 12, 670286, 2021 | 27 | 2021 |
| Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation ML Schubert, S Dietrich, S Stilgenbauer, A Schmitt, P Pavel, A Kunz, ... Biology of Blood and Marrow Transplantation 26 (9), 1575-1580, 2020 | 24 | 2020 |
| Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia … F Korell, ML Schubert, T Sauer, A Schmitt, P Derigs, TF Weber, ... Cancers 13 (7), 1684, 2021 | 23 | 2021 |
